Page 2 of 32 · 745 questions tagged clinical-trials.
For reference: SURMOUNT-OSA · 5 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…
I have the full paper rather than the abstract, and the supplementary appendix. I have used one of these for a while and I am considering switching, which requires a…
What I have: a GLP-1 receptor agonist · STEP 2. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I…
Details up front: vomiting · oral semaglutide · PIONEER-1. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I want to know whether this is a real physical effect or…
Details up front: SURMOUNT-2 · tirzepatide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence…
For reference: survodutide · room temperature. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one.…
Conditions: SURMOUNT-OSA · 15 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…
What I am working with: headache · a GLP-1 receptor agonist · TRIUMPH-1. I have read the primary source rather than the summary, which has left me with more…
Stated plainly: SURMOUNT-5 · tirzepatide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…
Stated plainly: early satiety · tirzepatide · SURPASS-2. I have read the primary source rather than the summary, which has left me with more questions. I understand…
For reference: SURMOUNT-OSA · hair thinning · 10 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is…
Details up front: dulaglutide · semaglutide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…
What I am working with: STEP 2 · vomiting. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…
The particulars: SURMOUNT-3 · tirzepatide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
I have the full paper rather than the abstract, and the supplementary appendix. I understand the observation; what I do not understand is the mechanism behind it. I…
Concretely: FLOW · semaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree, which…
Numbers first: tirzepatide · SURMOUNT-2. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I would…
For reference: 5 mg · ecnoglutide. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement than on…
My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I keep seeing this stated as a fact with no explanation attached,…
What I have: SURMOUNT-4 · early satiety. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
What I am working with: TRIUMPH-3 · injection-site erythema. I would like help reading this properly rather than being told what conclusion to reach. I have the full…
I have three data points across nine months, which I hope is enough to see a trend. I understand the observation; what I do not understand is the mechanism behind it.…
The particulars: STEP 5 · hair thinning · 2.4 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is…